{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T22:40:05Z","timestamp":1756680005092,"version":"3.44.0"},"publisher-location":"Cham","reference-count":42,"publisher":"Springer International Publishing","isbn-type":[{"type":"print","value":"9783030865818"},{"type":"electronic","value":"9783030865825"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1007\/978-3-030-86582-5_1","type":"book-chapter","created":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T03:04:20Z","timestamp":1630465460000},"page":"1-13","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Bioinformatic and MD Analysis of N501Y SARS-CoV-2 (UK) Variant"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-5024","authenticated-orcid":false,"given":"Marko","family":"Juki\u0107","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastjan","family":"Kralj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0538-2939","authenticated-orcid":false,"given":"Natalia","family":"Nikitina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Urban","family":"Bren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"issue":"4","key":"1_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.immuni.2020.03.007","volume":"52","author":"F Amanat","year":"2020","unstructured":"Amanat, F., Krammer, F.: SARS-CoV-2 vaccines: status report. Immunity 52(4), 583\u2013589 (2020)","journal-title":"Immunity"},{"key":"1_CR2","doi-asserted-by":"crossref","unstructured":"Banu, S., et al.: A distinct phylogenetic cluster of Indian severe acute respiratory syndrome coronavirus 2 isolates. Open Forum Infect. Dis. 7(11), ofaa434 (2020)","DOI":"10.1093\/ofid\/ofaa434"},{"issue":"1","key":"1_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41589-020-00679-1","volume":"17","author":"CJ Bracken","year":"2021","unstructured":"Bracken, C.J., et al.: Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2. Nat. Chem. Biol. 17(1), 113\u2013121 (2021)","journal-title":"Nat. Chem. Biol."},{"issue":"10","key":"1_CR4","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1002\/jcc.21287","volume":"30","author":"BR Brooks","year":"2009","unstructured":"Brooks, B.R., et al.: CHARMM: the biomolecular simulation program. J. Comput. Chem. 30(10), 1545\u20131614 (2009)","journal-title":"J. Comput. Chem."},{"key":"1_CR5","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.csbj.2018.01.002","volume":"16","author":"O Bu\u00df","year":"2018","unstructured":"Bu\u00df, O., Rudat, J., Ochsenreither, K.: FoldX as protein engineering tool: better than random based approaches? Comput. Struct. Biotechnol. J. 16, 25\u201333 (2018)","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"1_CR6","doi-asserted-by":"crossref","unstructured":"Chatterjee, P.: Covid-19: India authorises Sputnik V vaccine as cases soar to more than 180 000 a day BMJ 373, 978 (2021)","DOI":"10.1136\/bmj.n978"},{"issue":"2","key":"1_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s40475-020-00201-6","volume":"7","author":"WH Chen","year":"2020","unstructured":"Chen, W.H., Strych, U., Hotez, P.J., Bottazzi, M.E.: The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep. 7(2), 61\u201364 (2020)","journal-title":"Curr. Trop. Med. Rep."},{"key":"1_CR8","doi-asserted-by":"crossref","unstructured":"Cherian, S., et al.: Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. BioRxiv (2021)","DOI":"10.1101\/2021.04.22.440932"},{"issue":"8","key":"1_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E De Wit","year":"2016","unstructured":"De Wit, E., Van Doremalen, N., Falzarano, D., Munster, V.J.: SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14(8), 523\u2013534 (2016)","journal-title":"Nat. Rev. Microbiol."},{"key":"1_CR10","unstructured":"Faria, N.R., et al.: Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings. Virological (2021)"},{"key":"1_CR11","doi-asserted-by":"crossref","unstructured":"Gu, H., et al.: Adaptation of SARS-CoV-2 in BALB\/c mice for testing vaccine efficacy. Science 369(6511), 1603\u20131607 (2020)","DOI":"10.1126\/science.abc4730"},{"issue":"1","key":"1_CR12","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.antiviral.2013.08.015","volume":"100","author":"R Hilgenfeld","year":"2013","unstructured":"Hilgenfeld, R., Peiris, M.: From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses. Antivir. Res. 100(1), 286\u2013295 (2013)","journal-title":"Antivir. Res."},{"key":"1_CR13","unstructured":"Hopkins, J.: Mortality analyses. https:\/\/coronavirus.jhu.edu\/data\/mortality"},{"key":"1_CR14","doi-asserted-by":"crossref","unstructured":"Hui, D.S., et al.: The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health\u2013The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 91, 264\u2013266 (2020)","DOI":"10.1016\/j.ijid.2020.01.009"},{"issue":"11","key":"1_CR15","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","volume":"29","author":"S Jo","year":"2008","unstructured":"Jo, S., Kim, T., Iyer, V.G., Im, W.: CHARMM-GUI: a web-based graphical user interface for CHARMM. J. Comput. Chem. 29(11), 1859\u20131865 (2008)","journal-title":"J. Comput. Chem."},{"issue":"11","key":"1_CR16","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1097\/01.inf.0000188166.17324.60","volume":"24","author":"JS Kahn","year":"2005","unstructured":"Kahn, J.S., McIntosh, K.: History and recent advances in coronavirus discovery. Pediatr. Infect. Dis. J. 24(11), S223\u2013S227 (2005)","journal-title":"Pediatr. Infect. Dis. J."},{"key":"1_CR17","doi-asserted-by":"crossref","unstructured":"Khan, A., et al.: Higher infectivity of the SARS-CoV-2 new variants is associated with K417N\/T, E484K, and N501Y mutants: an insight from structural data. J. Cell. Physiol. (2021)","DOI":"10.1002\/jcp.30367"},{"key":"1_CR18","doi-asserted-by":"publisher","unstructured":"Krieger, E., Dunbrack, R.L., Hooft, R.W., Krieger, B.: Assignment of protonation states in proteins and ligands: combining pK a prediction with hydrogen bonding network optimization. In: Baron, R. (eds.) Computational Drug Discovery and Design. Methods in Molecular Biology (Methods and Protocols), vol. 819, pp. 405\u2013421. Springer, New York(2012). https:\/\/doi.org\/10.1007\/978-1-61779-465-0_25","DOI":"10.1007\/978-1-61779-465-0_25"},{"issue":"4","key":"1_CR19","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jmgm.2006.02.009","volume":"25","author":"E Krieger","year":"2006","unstructured":"Krieger, E., Nielsen, J.E., Spronk, C.A., Vriend, G.: Fast empirical pKa prediction by Ewald summation. J. Mol. Graph. Model. 25(4), 481\u2013486 (2006)","journal-title":"J. Mol. Graph. Model."},{"issue":"13","key":"1_CR20","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/jcc.23899","volume":"36","author":"E Krieger","year":"2015","unstructured":"Krieger, E., Vriend, G.: New ways to boost molecular dynamics simulations. J. Comput. Chem. 36(13), 996\u20131007 (2015)","journal-title":"J. Comput. Chem."},{"key":"1_CR21","doi-asserted-by":"crossref","unstructured":"Lan, J., et al.: Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581(7807), 215\u2013220 (2020)","DOI":"10.1038\/s41586-020-2180-5"},{"issue":"1","key":"1_CR22","doi-asserted-by":"publisher","first-page":"2002106","DOI":"10.2807\/1560-7917.ES.2020.26.1.2002106","volume":"26","author":"K Leung","year":"2021","unstructured":"Leung, K., Shum, M.H., Leung, G.M., Lam, T.T., Wu, J.T.: Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. Eurosurveillance 26(1), 2002106 (2021)","journal-title":"Eurosurveillance"},{"issue":"6","key":"1_CR23","doi-asserted-by":"publisher","first-page":"e00483","DOI":"10.1128\/AAC.00483-20","volume":"64","author":"H Li","year":"2020","unstructured":"Li, H., Zhou, Y., Zhang, M., Wang, H., Zhao, Q., Liu, J.: Updated approaches against SARS-CoV-2. Antimicrob. Agent. Chemother. 64(6), e00483 (2020)","journal-title":"Antimicrob. Agent. Chemother."},{"issue":"5","key":"1_CR24","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","volume":"182","author":"Li Q","year":"2020","unstructured":"Q, Li., et al.: The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182(5), 1284\u20131294 (2020)","journal-title":"Cell"},{"key":"1_CR25","unstructured":"Li, Q., et al.: Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. New Engl. J. Med. 382, 1199-1207 (2020)"},{"issue":"8","key":"1_CR26","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.tim.2015.06.003","volume":"23","author":"G Lu","year":"2015","unstructured":"Lu, G., Wang, Q., Gao, G.F.: Bat-to-human: spike features determining \u2018host jump\u2019of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 23(8), 468\u2013478 (2015)","journal-title":"Trends Microbiol."},{"issue":"10224","key":"1_CR27","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R., et al.: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395(10224), 565\u2013574 (2020)","journal-title":"Lancet"},{"key":"1_CR28","doi-asserted-by":"crossref","unstructured":"McKee, D.L., Sternberg, A., Stange, U., Laufer, S., Naujokat, C.: Candidate drugs against SARS-CoV-2 and COVID-19. Pharmacol. Res. 157, 104859 (2020)","DOI":"10.1016\/j.phrs.2020.104859"},{"issue":"5","key":"1_CR29","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3390\/v13050751","volume":"13","author":"K Moelling","year":"2021","unstructured":"Moelling, K.: Within-host and between-host evolution in SARS-CoV-2\u2013new variant\u2019s source. Viruses 13(5), 751 (2021)","journal-title":"Viruses"},{"key":"1_CR30","doi-asserted-by":"crossref","unstructured":"Naqvi, A.A.T., et al.: Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 1866(10), 165878 (2020)","DOI":"10.1016\/j.bbadis.2020.165878"},{"issue":"7844","key":"1_CR31","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41586-020-2918-0","volume":"590","author":"M O\u2019Driscoll","year":"2021","unstructured":"O\u2019Driscoll, M., et al.: Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 590(7844), 140\u2013145 (2021)","journal-title":"Nature"},{"key":"1_CR32","doi-asserted-by":"crossref","unstructured":"Shang, J., et al.: Structural basis of receptor recognition by SARS-CoV-2. Nature 581(7807), 221\u2013224 (2020)","DOI":"10.1038\/s41586-020-2179-y"},{"key":"1_CR33","unstructured":"Tegally, H., et al.: Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. MedRxiv (2020)"},{"issue":"2","key":"1_CR34","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/bib\/bbaa233","volume":"22","author":"S Teng","year":"2021","unstructured":"Teng, S., Sobitan, A., Rhoades, R., Liu, D., Tang, Q.: Systemic effects of missense mutations on SARS-CoV-2 spike glycoprotein stability and receptor-binding affinity. Brief. Bioinform. 22(2), 1239\u20131253 (2021)","journal-title":"Brief. Bioinform."},{"key":"1_CR35","unstructured":"Volz, E., et al.: Transmission of SARS-CoV-2 Lineage B. 1.1. 7 in England: Insights from linking epidemiological and genetic data. MedRxiv 2020, 12 (2021)"},{"issue":"10223","key":"1_CR36","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0140-6736(20)30185-9","volume":"395","author":"C Wang","year":"2020","unstructured":"Wang, C., Horby, P.W., Hayden, F.G., Gao, G.F.: A novel coronavirus outbreak of global health concern. Lancet 395(10223), 470\u2013473 (2020)","journal-title":"Lancet"},{"key":"1_CR37","doi-asserted-by":"crossref","unstructured":"Wang, W.B., Liang, Y., Jin, Y.Q., Zhang, J., Su, J.G., Li, Q.M.: E484K mutation in SARS-CoV-2 RBD enhances binding affinity with hACE2 but reduces interactions with neutralizing antibodies and nanobodies: Binding free energy calculation studies. bioRxiv (2021)","DOI":"10.1101\/2021.02.17.431566"},{"key":"1_CR38","doi-asserted-by":"crossref","unstructured":"Wibmer, C.K., et al.: SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma. Nat. Med. 27(4), 622\u2013625 (2021)","DOI":"10.1038\/s41591-021-01285-x"},{"issue":"7798","key":"1_CR39","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","volume":"579","author":"F Wu","year":"2020","unstructured":"Wu, F., et al.: A new coronavirus associated with human respiratory disease in china. Nature 579(7798), 265\u2013269 (2020)","journal-title":"Nature"},{"key":"1_CR40","doi-asserted-by":"crossref","unstructured":"Yadav, P., et al.: Neutralization of variant under investigation B. 1.617 with sera of BBV152 vaccinees. bioRxiv (2021)","DOI":"10.1101\/2021.04.23.441101"},{"key":"1_CR41","doi-asserted-by":"crossref","unstructured":"Yadav, P.D., et al.: SARS CoV-2 variant B. 1.617. 1 is highly pathogenic in hamsters than B. 1 variant. bioRxiv (2021)","DOI":"10.1101\/2021.05.05.442760"},{"issue":"6","key":"1_CR42","first-page":"505","volume":"158","author":"Y Zhang","year":"2015","unstructured":"Zhang, Y., et al.: Mutagenesis study to disrupt electrostatic interactions on the twofold symmetry interface of Escherichia coli bacterioferritin. J. Biochem. 158(6), 505\u2013512 (2015)","journal-title":"J. Biochem."}],"container-title":["IFIP Advances in Information and Communication Technology","Computer Science Protecting Human Society Against Epidemics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-86582-5_1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T22:02:11Z","timestamp":1756677731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-86582-5_1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9783030865818","9783030865825"],"references-count":42,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-86582-5_1","relation":{},"ISSN":["1868-4238","1868-422X"],"issn-type":[{"type":"print","value":"1868-4238"},{"type":"electronic","value":"1868-422X"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"2 September 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}},{"value":"Conflicts of Interest. The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"ANTICOVID","order":1,"name":"conference_acronym","label":"Conference Acronym","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"International Conference on Computer Science Protecting Human Society Against Epidemics","order":2,"name":"conference_name","label":"Conference Name","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"2021","order":5,"name":"conference_year","label":"Conference Year","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"28 June 2021","order":7,"name":"conference_start_date","label":"Conference Start Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"29 June 2021","order":8,"name":"conference_end_date","label":"Conference End Date","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"1","order":9,"name":"conference_number","label":"Conference Number","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"anticovid2021","order":10,"name":"conference_id","label":"Conference ID","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"https:\/\/confs.iitis.pl\/antycovid","order":11,"name":"conference_url","label":"Conference URL","group":{"name":"ConferenceInfo","label":"Conference Information"}},{"value":"Single-blind","order":1,"name":"type","label":"Type","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"EasyChair","order":2,"name":"conference_management_system","label":"Conference Management System","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"20","order":3,"name":"number_of_submissions_sent_for_review","label":"Number of Submissions Sent for Review","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"7","order":4,"name":"number_of_full_papers_accepted","label":"Number of Full Papers Accepted","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"4","order":5,"name":"number_of_short_papers_accepted","label":"Number of Short Papers Accepted","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"35% - The value is computed by the equation \"Number of Full Papers Accepted \/ Number of Submissions Sent for Review * 100\" and then rounded to a whole number.","order":6,"name":"acceptance_rate_of_full_papers","label":"Acceptance Rate of Full Papers","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"3","order":7,"name":"average_number_of_reviews_per_paper","label":"Average Number of Reviews per Paper","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"1","order":8,"name":"average_number_of_papers_per_reviewer","label":"Average Number of Papers per Reviewer","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}},{"value":"No","order":9,"name":"external_reviewers_involved","label":"External Reviewers Involved","group":{"name":"ConfEventPeerReviewInformation","label":"Peer Review Information (provided by the conference organizers)"}}]}}